NY-ESO-1 TCR Engineered T Cell and HSC After Melphalan Conditioning Regimen in Treating Participants with Recurrent or Refractory Ovarian, Fallopian Tube or Primary Peritoneal Cancer

Issue: October/November 2019

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Phase 1, open-label study evaluating the safety and efficacy of adoptive transfer of autologous NY-ESO-1 CD8-TCR engineered T cells and NY-ESO-1 CD4-TCR engineered hematopoietic stem cells after a myeloablative conditioning regimen, with administration of IL-2 in patients with relapsed or treatment-refractory ovarian, fallopian tube or primary peritoneal cancer.